US EditionNew Vaccine Designed to Help Fight Colorectal, Pancreatic Cancer Shows Promising Results: Study
The ELI-002 2P vaccine generated KRAS-specific T cells in 84% of patients and improved median relapse-free survival beyond 16 months, showing promise for hard-to-treat cancers.
- The Nature Medicine study reported that the off-the-shelf ELI-002 2P vaccine elicited immune responses in patients with pancreatic ductal adenocarcinoma and colorectal cancer, with 21 of 25 participants responding.
- About 90% of pancreatic cancers and 50% of colorectal cancers involve KRAS mutations, which have been a long-standing challenge to target in cancer therapy.
- Among participants, 84% generated KRAS-specific CD4+ helper and CD8+ killer T cells, with 67% developing immunity to additional tumor-associated mutations.
- With strong immune responses, median relapse-free survival was 16.33 months and median overall survival reached 28.94 months after 19.7 months of follow-up.
- Enrollment has closed in a larger Phase 2 study of ELI-002 7P, and the vaccine may help prevent or delay cancer regrowth in high-risk patients.
12 Articles
12 Articles
Novel vaccine shows promise against KRAS-driven pancreatic and colorectal cancers
A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown encouraging early results in patients with pancreatic and colorectal cancer, two of the most difficult-to-treat malignancies, according to a study led in part by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.
Vaccine elicits strong immune response in patients with pancreatic and colorectal cancer
A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown encouraging early results in patients with pancreatic and colorectal cancer, two of the most difficult-to-treat malignancies, according to a study led in part by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.
A new study from the University of California, in the United States, presented promising results from a vaccine that may be able to avoid recurrence of pancreatic cancer and colorectal cancer. The study is still in an initial phase and more research needs to be done in order to be able to reach a broader conclusion. Experts show that this can be a beneficial approach since this vaccine will be cheaper than others are developing for the same effe…
An experimental vaccine against mutations of the KRAS gene has shown efficacy against pancreatic cancer and colorectal cancer, according to the results of a phase 1 clinical trial led by the University of California in Los Angeles (UCLA). It is the so-called ELI-002 2P vaccine, which targets lymph nodes and attacks G12D and G12R mutations in the KRAS gene and can trigger powerful and lasting immune responses and help prevent or delay the recurre…
Off-the-Shelf Cancer Vaccine Elicits Strong Immune Response in Patients with Pancreatic and Colorectal Cancer
A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown encouraging early results in patients with pancreatic and colorectal cancer, two of the most difficult-to-treat malignancies, according to a study led in part by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
